BRIDION®

Drug Information Related Patent

Hold Company

MERCK SHARP DOHME

Learn More

Dosage and Administration

SOLUTION;INTRAVENOUS

Specification

EQ 500MG BASE/5ML (EQ 100MG BASE/ML); EQ 200MG BASE/2ML (EQ 100MG BASE/ML)

Indication

BRIDION® is indicated for reversal of neuromuscular blockade caused by rocuronium and vecuronium in adult and pediatric patients 2 years of age and older undergoing surgery.

Use

Instructions for Use

API

SUGAMMADEX SODIUM

API Structure

We Supply

SUGAMMADEX SODIUM

Note:

USP/CP/EP
Facility GMP
USMF/ASMF/CDE/DMF

null

Note:

null

Note:

null

Drug Patent

Patent No	Expiration Date
RE44733	2026/1/27

API Patent

Patent No	Expiration Date
RE44733	2026/1/27

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.

HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION

Tel:
E-mail:
Address:
WhatsAPP

Member of

CERTIFICATION